Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines

Radiology

Volumn 260, Issue 1, 2011, Pages 105-111

  Wang, Yingbing ^a   Alkasab, Tarik K ^a   Narin, Ozden ^a   Nazarian, Rosalynn M ^a   Kaewlai, Rathachai ^a   Kay, Jonathan ^b   Abujudeh, Hani H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ECHOVIST; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

ADULT; ARTICLE; BODY WEIGHT; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DRUG TOXICITY; FEMALE; GADOLINIUM; GUIDELINE ADHERENCE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MASSACHUSETTS; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 79959546471     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11102340     Document Type: Article

References (26)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356(9234):1000-1001.
2. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003;139(7):928-930. (Pubitemid 36898932)
3. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23(5):383-393. (Pubitemid 32938907)
4. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003;114(7):563-572. (Pubitemid 36577259)
5. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139(7):903-906. (Pubitemid 36898926)
6. Jiménez SA, Artlett CM, SandorfiN, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of infl ammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50(8):2660-2666. (Pubitemid 39062729)
7. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30(5):569-577. (Pubitemid 39447280)
8. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005;46(4):754-759. (Pubitemid 41383955)
9. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-1108.
10. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56(1):27-30. (Pubitemid 44969309)
11. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56(4):710-712. (Pubitemid 46400200)
12. Koreishi AF, Nazarian RM, Saenz AJ, et al. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med 2009;133(12):1943- 1948.
13. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008;190(4):1060-1068. (Pubitemid 351571526)
14. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18(10):2164-2173.
15. Lehnert T, Keller E, Gondolf K, Schäffner T, Pavenstädt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998;13(2):358-362. (Pubitemid 28062196)
16. Sterner G, Frennby B, Kurkus J, Nyman U. Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy? Scand J Urol Nephrol 2000;34(5):323-326.
17. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 2009;253(1):81-89.
18. Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol 2010;194(2):430-434.
19. Dang PA, Kalra MK, Schultz TJ, Graham SA, Dreyer KJ. Informatics in radiology: Render-an online searchable radiology study repository. RadioGraphics 2009;29(5):1233-1246.
20. Lin A, Harris MA, Zalis ME. Initial observations of electronic medical record usage during CT and MRI interpretation: frequency of use and impact on workflow. AJR Am J Roentgenol 2010;195(1):188-193.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation-Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130(6):461-470. (Pubitemid 29135798)
22. Abujudeh HH, Rolls H, Kaewlai R, et al. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009;30(6):1335-1340.
23. American College of Radiology. ACR manual on contrast media, version 7. http://www.acr.org/SecondaryMainMenuCategories/quality-safety/contrast-manual/ FullManual.aspx#page=8. Published 2010. Accessed November 16, 2010.
24. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248(3):807-816.
25. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001;42(3):339-341. (Pubitemid 33655068)
26. U.S. Food and Drug Administration. New warnings required on use of gadoliniumbased contrast agents. U.S. Food and Drug Administration Web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm225286.htm. Published September 9, 2010. Accessed November 16, 2010.